WEBULL

Breakeven On The Horizon For PYC Therapeutics Limited (ASX:PYC)

Simply Wall St · 1d ago

We feel now is a pretty good time to analyse PYC Therapeutics Limited's (ASX:PYC) business as it appears the company may be on the cusp of a considerable accomplishment. PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. On 30 June 2025, the AU$992m market-cap company posted a loss of AU$50m for its most recent financial year. Many investors are wondering about the rate at which PYC Therapeutics will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Consensus from 4 of the Australian Biotechs analysts is that PYC Therapeutics is on the verge of breakeven. They expect the company to post a final loss in 2027, before turning a profit of AU$100m in 2028. So, the company is predicted to breakeven approximately 3 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 28% is expected, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

earnings-per-share-growth
ASX:PYC Earnings Per Share Growth December 24th 2025

Given this is a high-level overview, we won’t go into details of PYC Therapeutics' upcoming projects, but, bear in mind that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

View our latest analysis for PYC Therapeutics

One thing we’d like to point out is that PYC Therapeutics has no debt on its balance sheet, which is rare for a loss-making biotech, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on PYC Therapeutics, so if you are interested in understanding the company at a deeper level, take a look at PYC Therapeutics' company page on Simply Wall St. We've also put together a list of essential factors you should further research:

  1. Valuation: What is PYC Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether PYC Therapeutics is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on PYC Therapeutics’s board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.